Two years after releasing the results of an independent study analyzing the workforce landscape and future talent needs of the Greater Philadelphia region’s cell and gene therapy sector, the Chamber of Commerce for Greater Philadelphia’s CEO Council for Growth and the University City Science Center are releasing a new and updated report. Among the key findings are: regional employment for cell and gene therapy companies has more than doubled since 2019 (up 127 percent); Greater Philadelphia will maintain its position as a leading R&D hub and will increasingly become a commercialization and manufacturing center; and there will be job opportunities at all levels, particularly as companies grow and begin building manufacturing capacity.
Economic consulting firm Econsult Solutions, Inc. (ESI) was reengaged to refresh and update the “Cell and Gene Therapy and Connected Health Workforce Analysis” completed in 2019-2020 to reflect changes in the industry. The result is a current and detailed workforce demand and supply study for Greater Philadelphia’s cell and gene therapy hub and recommendations for the region.
Strong cell and gene therapy employment growth has been seen across the region since 2019.
According to the 2019 study, that year there were approximately 4,900 employees working in the Greater Philadelphia region at cell and gene therapy companies, CMOS, biopharma companies, research organizations, or research hospitals in the cell and gene therapy fields. In 2022, that number is nearly 10,500.
- Regional employment for cell and gene therapy companies has more than doubled since 2019 (up 127 percent).
- Employees at contract manufacturing organizations have grown by nearly 40 percent since 2019.
- The number of employees at regional biopharma companies claiming cell and gene therapy-related skills has grown by more than 200 percent.
Existing cell and gene therapy company growth has been crucial.
While much of the growth in regional employment since 2019 has come from new companies or divisions focused on cell and gene therapy, examination of companies that had LinkedIn employment data in both 2019 and 2022 shows strong growth as well, coming from existing cell and gene therapy companies increasing employment by 67 percent over this time period.
Additional findings from the report include:
Leading R&D Hub Scenario
Projecting employment growth of between 25 percent and 50 percent over the next three years, Greater Philadelphia can expect total employment at cell and gene therapy companies and contract manufacturing organizations to be between 4,500 and 5,400 employees, with increasing shares of employees not requiring bachelor’s degrees.
Commercialization & Manufacturing Hub Scenario
Surveys and roundtable discussions with local industry experts point to Greater Philadelphia moving toward a commercialization & manufacturing hub scenario, with an accompanying increased need for manufacturing and quality assurance roles.
If the region can meet this goal, growth of 75 percent would result in 6,300 jobs at cell and gene therapy companies and contract manufacturing organizations by 2025, with up to 25 percent of those jobs being in manufacturing roles requiring fewer educational requirements.